Jagannath M. Sherigar

Jagannath M. Sherigar

Auto-generated profile, based on publicly available information

Jagannath M. Sherigar

New York Presbyterian Brooklyn Methodist Hospital, 506 6th Street, Brooklyn, NY 11215, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008
Verified
Journal Article
Closed access
SBStephen A Badger
Stephen A Badger
MOMark E O'Donnell
Mark E O'Donnell
JSJagannath M Sherigar
Jagannath M Sherigar
PCPeter Connolly
Peter Connolly
RSRoy Aj Spence
Roy Aj Spence

1 July 2017 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Open access
PDF file
JSJagannath M. Sherigar
Jagannath M. Sherigar
VGVijay Gayam
Vijay Gayam
AKArifa Khan
Arifa Khan
OMOsama Mukhtar
Osama Mukhtar
YAYavgeniy Arefiev
Yavgeniy Arefiev
SMSmruti R. Mohanty
Smruti R. Mohanty
There is a lack of evidence-based data on aged patients with newer direct-acting antivirals (DAAs) and with shorter duration of treatment regimens involving DAAs with or without ribavirin (RBV) and pegylated interferon (Peg IFN). Medical records of 240 patients treated with DAAs with or without Peg IFN and RBV between January 2013 and July 2015 were retrospectively analyzed. Patients were divided into two groups: patients aged 65 years and older (N=84) and patients aged younger than 65 years (N=156). Pretreatment baseline patient characteristics, treatment efficacy, factors affecting sustained virologic response at 12 weeks after treatment, and adverse reactions were compared between the groups. No statistically significant difference was observed with end of treatment response (98.8 vs. 98%, P=0.667) and sustained virologic response at 12 weeks after treatment (93.1 vs. 94.1%, P=0.767) between patients aged 65 and older and those younger than 65 years of age. Fatigue was the most common adverse event recorded (32.5%), followed by anemia (19.6%), leukopenia (11.7%), thrombocytopenia (10%), skin rash (8.3%), and headache (7.9%). The RBV dose was reduced in eight (8%) patients and four patients discontinued the RBV treatment because of severe anemia. RBV dose reduction or discontinuation did not reach statistical significance (P=0.913). Increased fibrosis, cirrhosis, aspartate aminotransferase, alanine aminotransferase, hemoglobin, and platelet levels seem to affect the sustained virologic response in the elderly. Twelve (6.28%) patients failed to respond to treatment and the failure rate was not significant (P=0.767) between the groups. DAAs with or without IFN and RBV in the standard recommended 12 or 24-week treatment regimens are effective, well tolerated, and may be safely extended to elderly patients infected with chronic hepatitis C. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/

17 October 2012 in Clinics and Practice
Verified
Journal Article
Open access
JSJagannath M. Sherigar
Jagannath M. Sherigar
RFRichard Fazio
Richard Fazio
MZMinsheng Zuang
Minsheng Zuang
EAEdward Arsura
Edward Arsura
Nitrofurantoin has been in use since 1953 as an effective agent for the prevention of recurrent urinary tract infection. It is associated with a wide range of adverse drug reactions. Chronic active hepatitis has increasingly been observed and many cases have been reported with case fatalities. We present a case of nitrofurantoin induced chronic active hepatitis and briefly review the serology and clinico pathological features of 57 similar cases reported in English literature. The consistent presence of antinuclear antibody, anti smooth muscle antibody, elevated immunoglobulin and pathological feature suggests an immunologic mechanism. Complete recovery is possible in most cases if medication is discontinued in time. Steroids may play a role in management if no improvement occurs despite discontinuation of medication. We suggest all patients who are on prolonged nitrofurantoin therapy be followed up with anti nuclear antibody, anti smooth muscle antibody, serum immunoglobulin and hepatic panel every three months.

6 July 2017 in Case Reports in Medicine
Verified
Journal Article
Open access
PDF file
JSJagannath M. Sherigar
Jagannath M. Sherigar
AYArefiev Yavgeniy
Arefiev Yavgeniy
DGDebra Guss
Debra Guss
NNNhu Ngo
Nhu Ngo
SMSmruti Mohanty
Smruti Mohanty
Autoimmune hepatitis (AIH) is a complex liver disease of unknown cause which results in immune-mediated liver injury with varied clinical presentations. Seronegative AIH follows a similar course to autoantibody-positive disease and diagnosis may be challenging. There are no single serologic tests of sufficient diagnostic specificity, and delay in appropriate treatment may lead to progression of the liver disease and liver failure. The revised conventional diagnostic criteria (RDC) scoring for AIH is complex and not routinely used in the clinical practice. The more recent simplified diagnostic criteria (SDC) scoring proposed by International Autoimmune Hepatitis Group in 2008 has wider application in routine practice facilitating the diagnosis of AIH with a specificity and sensitivity of ~90%. In this report, we describe a case of seronegative autoimmune hepatitis diagnosed using RDC. SDC score calculated in our case was 4 and was not diagnostic for AIH. We subsequently used the complex revised diagnostic criteria for definitive diagnosis. Some of the patients previously diagnosed as cryptogenic active hepatitis of unknown etiology probably had an unrecognized diagnosis of seronegative autoimmune hepatitis. SDC scoring may not be applicable in patients with seronegative autoimmune hepatitis. These patients should be reassessed by using RDC.

1 January 2007
Verified
Closed access
JSJagannath M Sherigar
Jagannath M Sherigar
BMBrendon McFall
Brendon McFall
JWJaweed Wali
Jaweed Wali

1 January 2016 in Journal of Community Hospital Internal Medicine Perspectives
Verified
Journal Article
Open access
PDF file
TSThein Swe
Thein Swe
ABAama Baqui
Aama Baqui
ANAkari Thein Naing
Akari Thein Naing
TBTajruba Baqui
Tajruba Baqui
JSJagannath Sherigar
Jagannath Sherigar
MMMohamed Mansour
Mohamed Mansour
Non-necrotizing colonic granuloma induced by schistosomiasis